We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Mutation Identified That Predicts Response of Breast Cancer to Treatment with Drug Duo

By LabMedica International staff writers
Posted on 17 Aug 2015
Print article
Image: Molecular model of phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) (Photo courtesy of Wikimedia Commons).
Image: Molecular model of phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) (Photo courtesy of Wikimedia Commons).
A gene mutation was identified as a biomarker that can predict whether a patient with HER-2 positive breast cancer will respond positively to the most effective dual anti-HER2 treatment.

Recent evidence has shown that the PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene was mutated in a range of human cancers. It has been found to be oncogenic and has been implicated in cervical cancers.

The phase II CHER-LOB (Chemotherapy, Herceptin, and Lapatinib in Operable Breast Cancer) study found in 2012 that the combination of trastuzumab plus lapatinib, added to neoadjuvant chemotherapy, was more effective than either agent alone. The CHER-LOB study was a noncomparative, randomized, phase II trial of preoperative taxane-anthracycline in combination with trastuzumab, lapatinib, or combined trastuzumab plus lapatinib in patients with human epidermal growth factor receptor 2 (HER2)-positive, stage II to IIIA operable breast cancer.

In a follow-up to the CHER-LOB study, investigators at Istituto Oncologico Veneto IRCCS (Padua, Italy) sought to identify biomarkers that would indicate which patients would benefit most (or least) from treatment with the trastuzumab plus lapatinib combination of chemotherapeutic drugs.

To this end they carried out genomic analyses on fresh-frozen tissue samples from 121 breast cancer patients positive for human epidermal growth factor 2 (HER2) who had been treated randomly with neoadjuvant chemotherapy plus trastuzumab, lapatinib, or both trastuzumab and lapatinib. Pre- and post-treatment samples were centrally evaluated for HER2, p95-HER2, phosphorylated AKT (pAKT), phosphatase and tensin homolog, Ki67, apoptosis, and PIK3CA mutations.

Results published in the August 5, 2015, online edition of the journal the Oncologist revealed that only 12.5% of patients with mutated PIK3CA responded to treatment with trastuzumab plus lapatinib, while the response rate to dual anti-HER2 therapy was four-times higher among patients with normal PIK3CA (48.4%). Thus, PIK3CA mutation could be a potential predictive marker of resistance to dual anti-HER2 treatment that should be further studied in breast cancer.

“We are seeing more and more anti-HER2 treatments becoming available to treat patients with HER2-positive breast cancer,” said senior author Dr. Pierfranco Conte, professor of medicine at Istituto Oncologico Veneto IRCCS. “By identifying new markers that help us to predict which patients are more sensitive to which anti-HER2 treatments, we are moving closer to treatment personalization.”

Related Links:

Istituto Oncologico Veneto IRCCS


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Reagent Reservoirs
Reagent Reservoirs

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.